Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine with Docetaxel vs. Irinotecan in Advanced NSCLC
NCT00004139Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Sep 1999
- Primary completion
- Jul 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Gemcitabine + Irinotecan with Gemcitabine + Docetaxel (2 arms). Primary endpoints: Complete and Overall Response Rate up to 2 years, Overall Survival up to 2 years and 1 more. Started Sep 1999; status: completed.
02
Drugs
gemcitabinedocetaxelirinotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00004139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004139.